Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

ANAB AnaptysBio Inc

17,22

0,37 (2,20%)

Zuletzt aktualisiert: 19:16:55

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more AnaptysBio Charts.

AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more AnaptysBio Charts.

News AnaptysBio Inc

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 15 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 7 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 7 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 7 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 7 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 7 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 7 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dienstag 7 Januar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 3 Januar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Mittwoch 18 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 11 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Mittwoch 11 Dezember 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere AnaptysBio Inc News-Artikel

Health Care Select Sector

Energy Select Sector SPDR

Invesco QQQ Trust Series 1

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen